IHI:NYE-iShares U.S. Medical Devices ETF (USD)

ETF | Health |

Last Closing

USD 63.98

Change

-0.72 (-1.11)%

Market Cap

N/A

Volume

1.21M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-25 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.27 (+0.86%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

+0.32 (+0.46%)

USD 2.77B
FXH First Trust Health Care AlphaD..

+0.39 (+0.35%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-0.56 (-0.62%)

USD 0.20B
IDNA iShares Genomics Immunology an..

-0.18 (-0.79%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.81 (-2.55%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.41 (+0.42%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.25 (-0.84%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-1.01 (-1.61%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.54 (-2.58%)

USD 6.67M

ETFs Containing IHI

MSSS Northern Lights Fund Trus.. 10.03 % 0.00 %

-0.13 (-0.46%)

USD 0.11B
ETAC:CA 0.00 % 1.76 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.65% 90% A- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.65% 90% A- 88% B+
Trailing 12 Months  
Capital Gain 11.29% 95% A 66% D+
Dividend Return 0.47% 44% F 5% F
Total Return 11.76% 95% A 59% D-
Trailing 5 Years  
Capital Gain 55.79% 90% A- 69% C-
Dividend Return 2.66% 47% F 6% D-
Total Return 58.45% 81% B- 63% D
Average Annual (5 Year Horizon)  
Capital Gain 3.00% 43% F 44% F
Dividend Return 3.41% 43% F 37% F
Total Return 0.42% 47% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 23.37% 38% F 47% F
Risk Adjusted Return 14.61% 43% F 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.